Pancreatic Islet and PARAthyroid Co-Transplantation for Treatment of Diabetes in IntraMuscular Site: PARADIGM
Transplantation of beta cells, contained in donor pancreatic islets, can reverse the symptoms of diabetes. However, due to a poor islet survival rate, transplants require islets from multiple donors. Since…
Phase 2 Safety and Efficacy Study of CLBS03 Autologous T-Regulatory Cells in Adolescents with Recent Onset Type 1 Diabetes Mellitus
Children with type 1 diabetes (T1D) face lifelong struggles with controlling their blood sugar levels and, despite careful management, an increased risk of severe complications. Currently, there is no approved therapy…
Clinical trial of directly vascularized islet cell replacement therapy for high-risk type 1 diabetes
ViaCyte is developing cell therapies to replace lost beta cells for people with type 1 diabetes (T1D). The therapies are derived from human embryonic stem cells, which are partially matured…
Preclinical and clinical testing of a stem cell-based combination product for insulin-dependent diabetes
ViaCyte is developing cell therapies to replace lost pancreatic beta cells for people with type 1 diabetes (T1D). The therapies are derived from human embryonic stem cells, which are partially…
Developing replacement islet cells for diabetes using human stem cells
Research Objective We will identify genetic regulators and intercellular signals that promote islet cell function, and apply our work to advance stem cell biology for generating replacement islets to reverse…
Immune cloaking of human stem cell-derived insulin-producing cells for curative cell therapy without immunosuppression
Research Objective The goal of our project is to generate cells for replacement therapy in patients that have reduced ability to trigger the immune response in the recipient and therefore…
Genome editing of human Tregs to enable combinational tolerogenic therapy with T cell-targeted biologics for T1D
Research Objective Genome-edited autologous regulatory T cells for promoting immune tolerance in combination with T-cell-targeting therapies Impact We focus on type 1 diabetes in this proof-of-concept study, but the therapeutic…